Welcome to our dedicated page for Clearside Biomed news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomed stock.
Clearside Biomedical, Inc. (symbol: CLSD) is a prominent clinical biopharmaceutical company based in Alpharetta, Georgia. Specializing in the development of pharmacological therapies, the company's primary focus is on treating blinding diseases of the eye through their innovative suprachoroidal space (SCS) technology.
Clearside Biomedical's cornerstone is their SCS Microinjector®, a proprietary device that facilitates a non-surgical, office-based procedure. This technology allows for targeted delivery of therapies directly to the macula, retina, or choroid, which could potentially preserve and enhance vision for patients suffering from severe eye conditions.
One of the company's significant achievements is the robust safety profile and encouraging efficacy data from multiple studies using the SCS Microinjector®. These findings have been featured in numerous oral and poster presentations, highlighting the potential of Clearside’s technology in ophthalmic therapeutics.
Clearside Biomedical continues to advance its pipeline of ophthalmic therapies, collaborating with various partners to bring innovative treatments to market. The company remains committed to improving the quality of life for individuals with vision-threatening diseases through groundbreaking research and development.
Recent Achievements:
- Clinical data utilizing Clearside’s suprachoroidal delivery technology featured in multiple presentations.
- Enhanced safety and efficacy data presented, showcasing the utility of the SCS Microinjector®.
Investors and media can reach out to Jenny Kobin and Remy Bernarda for more information at ir@clearsidebio.com or by calling (678) 430-8206.
Clearside Biomedical (NASDAQ:CLSD) announced it will report its fourth quarter and full year 2020 financial results on March 10, 2021, after market close. A conference call will follow at 4:30 p.m. ET for a discussion of the results and corporate updates. The event will be accessible via the company's Investors section on their website. Clearside specializes in treatments for severe back-of-the-eye diseases, utilizing its SCS Microinjector technology for targeted delivery of medications.
Clearside Biomedical, a biopharmaceutical company focused on vision restoration, will participate in two investor conferences in March 2021. The first is the Cowen 41st Annual Health Care Conference on March 2, at 2:10 pm ET, focusing on clinical development. The second event is the 33rd Annual ROTH Conference on March 16, at 9:00 am ET, featuring an ophthalmology panel. Both panels will be accessible online, and management will engage in live, virtual one-on-one meetings with registered investors.
Clearside Biomedical (NASDAQ:CLSD) presented the delivery method of axitinib for wet AMD at a recent conference. Dr. David M. Brown highlighted its advantages, including ease of administration and superior potency compared to existing treatments. Preclinical studies showed that Clearside's suprachoroidal delivery of axitinib (CLS-AX) resulted in significantly higher drug levels in tissues, potentially reducing side effects and treatment burden. The ongoing Phase 1/2a OASIS trial aims to assess the safety and tolerability of CLS-AX, with initial results expected mid-2021.
Clearside Biomedical (NASDAQ:CLSD) announced significant clinical findings at the 44th Virtual Annual Macula Society Meeting, showcasing their suprachoroidal injection platform's potential for treating various retinal disorders. Notably, CLS-AX, an injectable suspension of axitinib, is currently in a Phase 1/2a trial for wet age-related macular degeneration. The SCS Microinjector has facilitated over 1,000 injections, demonstrating broad applicability, safety, and efficacy in conditions like macular edema and diabetic retinopathy. Upcoming presentations at conferences further highlight their innovative treatment strategies.
Clearside Biomedical, Inc. (NASDAQ:CLSD) has announced the enrollment of the first patients in its Phase 1/2a clinical trial for CLS-AX, a novel axitinib injectable suspension for treating wet age-related macular degeneration (AMD). The trial, named OASIS, aims to assess the safety and tolerability of CLS-AX via suprachoroidal injection. The study will include 15 patients across 3 cohorts with varying dosage levels. Positive preclinical results indicate that CLS-AX could alleviate treatment burdens compared to existing therapies. Initial data is expected in mid-2021.
Clearside Biomedical (NASDAQ:CLSD) has announced a securities purchase agreement with institutional investors for the sale of 4,209,050 shares of common stock at $2.851 per share, totaling approximately $12.0 million in gross proceeds. This registered direct offering is priced based on the five-day average closing price and is expected to close on January 8, 2021. Roth Capital Partners is the sole placement agent for the offering, which is part of a previously filed shelf registration statement with the SEC.
Clearside Biomedical (Nasdaq: CLSD) announced two presentations of its preclinical and clinical data at the virtual AAO 2020 Annual Meeting. A recent publication highlights the clinical characterization of a suprachoroidal injection procedure across three retinal disorders. Dr. Thomas A. Ciulla noted the success of 33 presentations throughout the year and the anticipated data from CLS-AX in 2021. The platform is designed for targeted, compartmentalized delivery of ocular therapies, including ongoing partnerships that feature Clearside's SCS Microinjector for gene therapy and melanoma.
Clearside Biomedical, a biopharmaceutical company focused on vision restoration treatments, will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 8:40 a.m. ET. The presentation will be accessible via a live webcast on the Clearside website, with an archived version available for three months. Clearside specializes in innovative approaches to treat serious back of the eye diseases using their proprietary SCS Microinjector technology, which allows targeted delivery of treatments.
Clearside Biomedical (NASDAQ:CLSD) announced the initiation of a Phase 1/2a trial for CLS-AX aimed at treating wet age-related macular degeneration (AMD) by year-end 2020. The company reported Q3 2020 financial results, showing license revenue of $3.4 million, a significant increase from $141,000 in Q3 2019, mainly due to a partner milestone payment. Research expenses rose to $3.5 million, partly due to preparations for CLS-AX, while the net loss decreased to $2.4 million, or $0.05 per share. Clearside expects to have sufficient resources to fund operations into Q3 2021.
Clearside Biomedical (NASDAQ:CLSD) will report its third quarter 2020 financial results on November 10, 2020, after market close. A webcast and conference call are scheduled for 4:30 PM ET for discussions on these results and corporate updates. Clearside specializes in treatments aimed at restoring vision for patients with serious eye diseases, utilizing a flexible, non-surgical SCS Microinjector® to deliver targeted therapies.
FAQ
What is the current stock price of Clearside Biomed (CLSD)?
What is the market cap of Clearside Biomed (CLSD)?
What does Clearside Biomedical, Inc. specialize in?
Where is Clearside Biomedical, Inc. located?
What is the SCS Microinjector®?
How does Clearside Biomedical's technology benefit patients?
What recent achievements has Clearside Biomedical reported?
Who can be contacted for investor and media inquiries?
What kind of presentations feature Clearside's technology?
What diseases is Clearside Biomedical targeting with their therapies?
Is Clearside Biomedical's procedure surgical?
What is the significance of Clearside's technology in ophthalmology?
